January 29, 2015 3:25 PM ET


Company Overview of Diasome Pharmaceuticals, Inc.

Company Overview

Diasome Pharmaceuticals, Inc., a clinical stage diabetes therapeutics company, designs and develops insulin-based therapies for the treatment of diabetes in the United States. The company’s products include Oral HVD-I, a targeted oral insulin in a pill or gel cap dose form; HDV-I, an injectable short acting insulin; and HDV-B, an injectable basal long acting insulin. It develops products for patients suffering from Type 1 and Type 2 diabetes. Diasome Pharmaceuticals, Inc. was founded in 2004 and is based in Cleveland, Ohio.

10000 Cedar Avenue

Suite 6

Cleveland, OH 44106

United States

Founded in 2004



Key Executives for Diasome Pharmaceuticals, Inc.

Scientific Advisor
Scientific Advisor
Compensation as of Fiscal Year 2014.

Similar Private Companies By Industry

Company Name Region
OCT Group LLC United States
DRJ Group, Inc. United States
Health Maintenance Programs, Inc. United States
Trigemina, Inc. United States
AkaRx, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Diasome Pharmaceuticals, Inc., please visit www.diasome.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.